Bellus Health Inc

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today reported its financial and operating results for the first quarter ending March 31, 2022. “This quarter, we have focused our efforts on our clinical plans for BLU-5937, our highly selective, second generation

BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American Thoracic Society (ATS) 2022 International Conference, being held in

BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that the Company's management team will participate in multiple upcoming investor conferences. Presentation Details: Event: 2022 Bloom Burton & Co. Healthcare Investor Conference Date/Time: Monday,

BELLUS Health to Participate in Multiple Upcoming Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 70.5% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Bellus (BLU) Climb 70% to Reach the Level Wall Street Analysts Expect?

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a panel at the Cowen & Co. 42nd Annual Health Care Conference. Panel Details: Event: Cowen & Co.

BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference

The consensus price target hints at an 87.5% upside potential for Bellus (BLU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Bellus (BLU) Climb 88% to Reach the Level Wall Street Analysts Expect?

Bellus (BLU) delivered earnings and revenue surprises of 35.71% and 60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, today reported its financial and operating results for the year ending December 31, 2021. “2021 was a momentous year for BELLUS Health, underscored by positive topline results from the Phase 2b SOOTHE trial and developments w

BELLUS Health Reports Year 2021 Financial Results and Business Highlights

Bellus (BLU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Bellus (BLU) Rating Upgrade to Buy

The average of price targets set by Wall Street analysts indicates a potential upside of 65% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 65% Upside in Bellus (BLU): Here's What You Should Know

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 25,000,000 common shares at a price to the public of US$8.00 per common share. The total gross proceeds to the Company were US$200 million, before deducting the underwriting commissions and any expenses related to the Offering. Bellus has also g

BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and including LifeSci Capital as lead manager and H.C. Wainwright & C

BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.

Bellus (BLU) Stock Surges on Data From Chronic Cough Study

BELLUS achieved primary endpoint of phase 2b SOOTHE study using BLU-5937 in patients with refractory chronic cough. An end of phase 2b meeting with the FDA for BLU-5937 in refractory chronic cough is expected in Q2 of 2022, with phase 3 study likely to start in 2nd half of 2022.

BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients

A phase 2 trial with the company's chronic-cough candidate hit its primary endpoint.

Here's Why Bellus Health Is Jumping Higher Today

BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937. The post BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today appeared first on InvestorPlace.

BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today

The shares of Bellus Health Inc (NASDAQ:BLU) are soaring today, up 63% to trade at $9.13 at last check, after the Canada-based drug name announced positive results from a mid-stage study of its cough therapy drug candidate, BLU-5937.

Pharma Stock Hits Annual High on Study Results

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in

BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in BELLUS Health (BLU) Stock?

Bellus (BLU) delivered earnings and revenue surprises of -20.83% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Bellus Health (BLU) Reports Q3 Loss

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ending September 30, 2021. “We are pleased with the substantial progress we have made advancing our two ongoing Phase 2 trials this quarter, a

BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights

CytoDyn Inc.

Diffusion Pharmaceuticals

Entera Bio Ltd

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appeared first on InvestorPlace.

7 Biotech Penny Stocks With Huge Catalysts Coming in 2022

Kadmon Hlds

Leap Therapeutics

Find out why last month was a big one for these three drugmakers.

3 Biotech Stocks That Surged in September

BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.

BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough (“RCC”) and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic prurit

BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis

News for Bellus Health Inc Stock (BLU)